. 2023 Jan 18;39:100585. doi: 10.1016/j.ctro.2023.100585

Table 1.

Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria and justifications
• Age ≥35 years. • Male or female. • New radiological diagnosis of glioblastoma. • Performance status judged by World Health Organisation, Eastern Cooperative Oncology Group [ECOG] score = 0–1. • Case has been reviewed by Neuro-oncology multidisciplinary team (MDT – neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative radiotherapy based on available clinical information and imaging. • Confirmation at first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure). • Intention to treat with surgical resection and postoperative adjuvant therapy as per current standard of care (Stupp regimen). • Tumour size, location and configuration meet radiotherapy treatment planning criteria (e.g. to secure cold spot/hot spot, meets dose constraints for organs at risk when accounting for post-operative radiotherapy). • Adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, eGFR >30 ml/min). • Mental capacity to consent for treatment. • Able and willing to give informed consent.	• Planned biopsy procedure only. Suspicion of other tumour on CT body scan or known malignancy except non-melanoma skin cancer, completely resected cervical or prostate cancer (with Prostate Specific Antigen of less than or equal to 0.1 ng/ml) within the past 3 years. Contraindications to contrast-enhanced MRI scanning (e.g. claustrophobia, gadolinium allergy).

Inclusion criteria

Exclusion criteria and justifications

•
Age ≥35 years.
•
Male or female.
•
New radiological diagnosis of glioblastoma.
•
Performance status judged by World Health Organisation, Eastern Cooperative Oncology Group [ECOG] score = 0–1.
•
Case has been reviewed by Neuro-oncology multidisciplinary team (MDT – neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative radiotherapy based on available clinical information and imaging.
•
Confirmation at first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure).
•
Intention to treat with surgical resection and postoperative adjuvant therapy as per current standard of care (Stupp regimen).
•
Tumour size, location and configuration meet radiotherapy treatment planning criteria (e.g. to secure cold spot/hot spot, meets dose constraints for organs at risk when accounting for post-operative radiotherapy).
•
Adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, eGFR >30 ml/min).
•
Mental capacity to consent for treatment.
•
Able and willing to give informed consent.

•
Planned biopsy procedure only.

Suspicion of other tumour on CT body scan or known malignancy except non-melanoma skin cancer, completely resected cervical or prostate cancer (with Prostate Specific Antigen of less than or equal to 0.1 ng/ml) within the past 3 years.

Contraindications to contrast-enhanced MRI scanning (e.g. claustrophobia, gadolinium allergy).